Comet Bio Denmark ApS - CVR: 43297333

2022, DKK

02.08.2023

Bruttoresultat

-5.044'

Primær drift

-5.406'

Årets resultat

-4.033'

Aktiver

3.388'

Kortfristede aktiver

2.470'

Egenkapital

-3.993'

Afkastningsgrad

-160 %

Soliditetsgrad

-118 %

Likviditetsgrad

33 %

Resultat

02.08.2023

Årsrapport	2022 02.08.2023
Nettoomsætning
Bruttoresultat	-5.043.974
Resultat af primær drift	-5.405.830
Indtægter af kapitalandele (tilknyttede og associerede)	0
Finansielle indtægter	1.372.846
Finansieringsomkostninger	0
Andre finansielle omkostninger	0
Resultat før skat	-4.032.984
Resultat	-4.032.984
Forslag til udbytte	0

Aktiver

02.08.2023

Årsrapport	2022 02.08.2023
Kortfristede varebeholdninger	419.351
Kortfristede tilgodehavender fra salg og tjenesteydelser	2.050.711
Likvider	0
Kortfristede aktiver	2.470.062
Immaterielle aktiver og goodwill	0
Finansielle anlægsaktiver	0
Materielle aktiver	918.010
Langfristede aktiver	918.010
Aktiver	3.388.072

Aktiver

02.08.2023

Passiver

02.08.2023

Årsrapport	2022 02.08.2023
Forslag til udbytte	0
Egenkapital	-3.992.984
Hensatte forpligtelser	0
Langfristet gæld til banker	0
Leverandører af varer og tjenesteydelser	2.325.949
Kortfristede forpligtelser	7.381.056
Gældsforpligtelser	7.381.056
Forpligtelser	7.381.056
Passiver	3.388.072

Passiver

02.08.2023

Nøgletal

02.08.2023

Årsrapport	2022 02.08.2023
Afkastningsgrad	-159,6 %
Dækningsgrad	Na.
Resultatgrad	Na.
Varelagerets omsætningshastighed	Na.
Egenkapitals-forretning	101,0 %
Payout-ratio	Na.
Gældsdæknings-nøgletal	Na.
Soliditestgrad	-117,9 %
Likviditetsgrad	33,5 %

Resultat

02.08.2023

Gæld

02.08.2023

Årsrapport

02.08.2023

Nyeste:09.05.2022- 31.12.2022(offentliggjort: 02.08.2023)

Information om virksomhedens regnskabsklasse:The annual report of Comet Bio Denmark ApS for 2022 has been presented in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B.

Oplysning om eventualaktiver:3. Contingent assets The Company has a deferred tax asset of DKK 887,000, which has not been recognised in the balance sheet. The tax asset can be attributed to tax losses carried forward which are not expected to be utilised within the next 3-5 years. The tax asset can be carried forward indefinitely.

Beretning

02.08.2023

Dato for ledelsens godkendelse af årsrapporten:2023-07-31

Ledelsespåtegning: Management has today considered and approved the annual report for the financial year 09. May 2022 - 31. December 2022 for Comet Bio Denmark ApS. The Annual Report, which has not been audited, is presented in accordance with the Danish Financial Statements Act. Management believes that the financial statements give a true and fair view of the company's assets, liabilities and financial position and of the result. The conditions for not conducting an audit of the Financial Statement have been met. The annual report is submitted for approval by the General Assembly. Kalundborg, 31 July 2023 Management Richard Lloyd Troyer Manager

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Management has today considered and approved the annual report for the financial year 09. May 2022 - 31. December 2022 for Comet Bio Denmark ApS.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:The Company's principal activities The Company's principal activities is to operate a business with manufacturing and/or distribution of food ingredients for sustainable products, as well as related business.